重塑全球药企版图！阿斯利康拟洽购百时美施贵宝，或缔造史上最大医药并购案

智通财经08-03

智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。上述知情人士补充称，两家公司已就合并事宜举行早期阶段磋商，因事项尚未公开而不愿具名。这些知情人士提醒称，目前尚不清楚磋商是否仍在继续，也不确定是否会转化为实际交易。市值达 1334 亿美元的百时美施贵宝，可为阿斯利康在美国市场提供更庞大的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2656346866?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2026-08-03 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656346866","market":"us","top_or_hot":-1,"title":"重塑全球药企版图！阿斯利康拟洽购百时美施贵宝，或缔造史上最大医药并购案","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。上述知情人士补充称，两家公司已就合并事宜举行早期阶段磋商，因事项尚未公开而不愿具名。这些知情人士提醒称，目前尚不清楚磋商是否仍在继续，也不确定是否会转化为实际交易。市值达 1334 亿美元的百时美施贵宝，可为阿斯利康在美国市场提供更庞大的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1475024.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>重塑全球药企版图！阿斯利康拟洽购百时美施贵宝，或缔造史上最大医药并购案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n重塑全球药企版图！阿斯利康拟洽购百时美施贵宝，或缔造史上最大医药并购案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-03 07:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1475024.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。上述知情人士补充称，两家公司已就合并事宜举行早期阶段磋商，因事项尚未公开而不愿具名。这些知情人士提醒称，目前尚不清楚磋商是否仍在继续，也不确定是否会转化为实际交易。市值达 1334 亿美元的百时美施贵宝，可为阿斯利康在美国市场提供更庞大的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1475024.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FTXH","symbol_name":"First Trust Nasdaq Pharmaceuticals ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1475024.html","article_id":"2656346866","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656346866","pubTimestamp":1785713456,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据知情人士透露，阿斯利康已就收购百时美施贵宝展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。阿斯利康市值超过百时美施贵宝百时美施贵宝正为其部分最核心产品面临专利保护到期做准备，包括抗凝药艾乐妥与抗癌药欧狄沃。两款产品合计约占百时美施贵宝销售额的一半。上周，百时美施贵宝公布季度销售额 130 亿美元，创历史最高。阿斯利康目前是伦敦证券交易所市值第二大的公司。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","XBIX":"Corgi U.S. Biotech 2x Daily ETF","LU1032466523.USD":"高盛全球多资产收益组合Acc","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4559":"巴菲特持仓","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","JHMH":"John Hancock Multifactor Healthcare ETF","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","FHLC":"Fidelity MSCI Health Care Index","SYNB":"PUTNAM BIOREVOLUTION ETF","IEHS":"iShares Evolved U.S. Healthcare Staples ETF","LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","MEDI":"HARBOR HEALTH CARE ETF","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","AZNH":"ASTRAZENECA PLC ADRhedged","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2473716301.USD":"ALLIANZ GLOBAL INTELLIGENT CITIES INCOME \"AMF\" (USD) INC","BK4581":"高盛持仓","IHE":"iShares U.S. Pharmaceuticals ETF","RXL":"ProShares Ultra Health Care","PPH":"VanEck Pharmaceutical ETF","FXH":"First Trust Health Care AlphaDEX Fund","AZN":"阿斯利康","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","PILL":"Direxion Daily Pharmaceutical & Medical Bull 3X Shares","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4534":"瑞士信贷持仓","CURE":"Direxion Daily Healthcare Bull 3X Shares","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BMY":"施贵宝","RXD":"ProShares UltraShort Health Care","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","XPH":"SPDR S&P Pharmaceuticals ETF","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC"},"translate_title":"Reshape the global pharmaceutical company landscape! AstraZeneca intends to negotiate to acquire Bristol-Myers Squibb, or create the largest pharmaceutical merger and acquisition in history","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/cf4fba25abbf5056c25053b0ee7ee973","symbols_score_info":{"BMY":1.5,"MEDI":1.5,"AZNH":0.6,"PPH":1.5,"IEHS":1.5,"PILL":1.5,"IHE":1.5,"XBIX":1.5,"FXH":1.5,"CURE":1.5,"FHLC":1.5,"AZN":1.5,"JHMH":1.5,"FTXH":0.6,"SYNB":1.5,"XPH":1.5,"RXL":1.5,"RXD":1.5},"content_text":"智通财经APP获悉，据知情人士透露，阿斯利康(AZN.US)已就收购百时美施贵宝(BMY.US)展开探讨，这桩超级交易若达成，将缔造全球规模最大的制药企业之一。上述知情人士补充称，两家公司已就合并事宜举行早期阶段磋商，因事项尚未公开而不愿具名。这些知情人士提醒称，目前尚不清楚磋商是否仍在继续，也不确定是否会转化为实际交易。市值达 1334 亿美元的百时美施贵宝，可为阿斯利康在美国市场提供更庞大的立足点。阿斯利康市值约为 1959 亿英镑(2644 亿美元)。阿斯利康市值超过百时美施贵宝百时美施贵宝正为其部分最核心产品面临专利保护到期做准备，包括抗凝药艾乐妥(Eliquis)与抗癌药欧狄沃(Opdivo)。两款产品合计约占百时美施贵宝销售额的一半。上周，百时美施贵宝公布季度销售额 130 亿美元，创历史最高。增长主要来自较新产品——血液肿瘤疗法 Breyanzi、皮肤癌药物 Opdualag 与心脏病药物 Camzyos。在首席执行官帕斯卡尔·索利奥特带领下，阿斯利康凭借一系列重磅药物已成为抗癌药领域的巨头。索利奥特 2012 年接任 CEO 后不久，便击退了辉瑞的收购企图，后者因担忧失去一家关键英国企业而引发英国政府介入。阿斯利康目前是伦敦证券交易所市值第二大的公司。公司正日益向美国倾斜，去年将其美国股票挂牌从纳斯达克的美股存托凭证(ADR)升级至纽约证券交易所，同时保留伦敦的总部与主要上市地位。这家制药商正朝着 2030 年销售额 800 亿美元的雄心目标推进，并希望凭借多款在研药物打入利润丰厚的减重市场。索利奥特此前告诉媒体，当有人向他推介公司核心领域之外的疾病项目时，\"我总是说不，因为一旦超出自己的专业领域，下错注的风险会迅速攀升。\"瑞穗一位分析师认为，投资者可能会对合并设想表示反对，因为阿斯利康未来五年每股收益预计将实现 10% 或更高的增长，而百时美施贵宝的每股收益在本十年剩余时间里可能下滑。\"投资者会主张阿斯利康并不需要百时美施贵宝，反过来的情况才成立；除非存在能抵消收入/盈利下滑的大规模交易协同效应，否则这桩合并很难站得住脚，\"瑞穗医疗行业专家贾里德·霍尔兹在周日的一份报告中写道。不过霍尔兹表示，他的第一反应是，\"如果要说史上曾有适合做这种交易的时候，那大概就是现在，\"他援引特朗普政府对并购活动相当宽松的立场作为依据。若交易达成，它将跻身史上最大制药交易，超越百时美施贵宝 2019 年以 740 亿美元收购新基(Celgene)的交易。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656346866","isCrawlerRequest":true}